SCLC Treatment - Extensive Disease

SCLC: Results from the Southwest Oncology Group (Medscape)
Summary, by Paul Bunn, MD, of findings presented during the 9th World Conference on Lung Cancer (September 2000). Discusses the Southwest Oncology Group (SWOG) Phase II study of paclitaxel/etoposide/cisplatin (PET) plus G-CSF in patients with extensive-stage SCLC. Aimed at physicians. Registration required for free access to Medscape. [9/00]

SCLC: Extensive disease - Recent MEDLINE Abstracts (PubMed)

Camptosar (irinotecan) Plus Cisplatin Increases Survival in Small Cell Lung Cancer (Doctor's Guide)
Reports that Camptosar (also known as irinotecan or CPT-11) in combination with cisplatin increased survival compared with the standard treatment (etoposide and cisplatin) for patients with extensive small cell lung cancer, according to a Phase III study presented at ASCO 2000. [5/00]

Four-Drug Regimen Enhances Responses and Increases Survival
(cancereducation.com)
v.9, no.11, Suppl. 6 Oncology News (November 2000)
Reports study results that found patients with extensive SCLC experienced better outcomes with a four-drug regimen of epirubicin (Ellence), cyclophosphamide (Cytoxan), etoposide (VePesid) and cisplatin (Platinol) than with the commonly used combination of etoposide and cisplatin. Registration required for free access. [11/00]